[ad_1]
Contract maker Catalent Inc. has agreed to buy $ 1.2 billion for Paragon Bioservices Inc., according to sources familiar with the issue, the latest emerging market agreement for gene therapy drugs.
The deal, which should be announced Monday morning, would allow Catalent to expand its gene therapy manufacturing capabilities, officials said. The transaction is expected to close in the second quarter.
…
[ad_2]
Source link